Erik Wallstroem, MD, PhD, Global Head of Development, Neurology and Opthalmology, Sanofi, and Tom Snow, VP, Global Franchise Head, Neurology and Rare Blood Disorders, Sanofi, explore the current treatment landscape for multiple sclerosis (MS), emphasizing the existing gaps and hopes for future therapies. Despite significant advancements in MS treatments over the past decades, certain patient subgroups, especially those with smoldering MS, continue to experience progression. This progression is believed to be driven by compartmentalized neuroinflammation within the central nervous system, untouched by current therapies. They highlight their hopes for BTK inhibitors, including tolebrutininb, to address this unmet need. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
